Research background · Updated November 1, 2026
Retatrutide Research: Publications, Study Types and Background
Short answer
Retatrutide is listed as gIP, GLP-1 and glucagon receptor triple agonist peptide. As of November 1, 2026, PubMed indexes 208 records matching Retatrutide, the earliest from 2023; 112 were published in 2021–2025 and 129 are reviews. ClinicalTrials.gov lists 34 registered studies matching the compound.
- PubMed records
- 208
- Earliest record
- 2023
- Published 2021–2025
- 112
- Reviews
- 129
- Animal-only studies
- 10
- Registered studies
- 34
Publications per year, 2006–2025
119 records in 2016–2025 against 0 in 2006–2015; the busiest year was 2025, with 58.
See the numbers
| Year | PubMed records |
|---|---|
| 2006 | 0 |
| 2007 | 0 |
| 2008 | 0 |
| 2009 | 0 |
| 2010 | 0 |
| 2011 | 0 |
| 2012 | 0 |
| 2013 | 0 |
| 2014 | 0 |
| 2015 | 0 |
| 2016 | 0 |
| 2017 | 0 |
| 2018 | 0 |
| 2019 | 0 |
| 2020 | 0 |
| 2021 | 0 |
| 2022 | 0 |
| 2023 | 16 |
| 2024 | 45 |
| 2025 | 58 |
Study types
| All PubMed records | 208 |
|---|---|
| Reviews | 12962% |
| Animal studies (no human subjects indexed) | 105% |
| Indexed as clinical trials | 105% |
| Registered on ClinicalTrials.gov | 34 |
Categories overlap and follow PubMed’s own indexing; recent records may not be indexed yet.
Primary research directions
What 4 of the most-cited and most recent Retatrutide papers report, in their own authors’ terms. Each line links the paper it came from.
Triple GIP, GLP-1 and glucagon receptor agonism
This phase 2 randomized trial in adults with type 2 diabetes studied retatrutide, a single peptide with agonist activity at the GIP, GLP-1 and glucagon receptors, against placebo and dulaglutide for change in HbA1c at 24 weeks and in body weight at 36 weeks, following phase 1 findings of glucose and body-weight lowering.
HumansRosenstock J 2023Lancet (London, England)PMID 37385280
Body weight and energy balance
In a 48-week phase 2 placebo-controlled trial in 338 adults with obesity, mean body weight fell by 24.2% in the highest retatrutide group against 2.1% with placebo; the most common adverse events were gastrointestinal, mostly mild to moderate.
HumansJastreboff AM 2023The New England journal of medicinePMID 37366315
Glycemic control
This narrative review reports that phase 1 to 3 trials of retatrutide showed reductions in body weight and favorable glycemic control, and states that its long-term safety profile and use in special populations still need to be defined.
ReviewAbdul-Rahman T 2024European journal of pharmacologyPMID 39515565
Liver fat
In a randomized placebo-controlled substudy of 98 adults with metabolic dysfunction-associated steatotic liver disease, mean liver fat fell by 43% to 82% from baseline at 24 weeks across the retatrutide groups against no change with placebo, and the reductions were related to changes in body weight, abdominal fat and markers of insulin sensitivity and lipid metabolism.
HumansSanyal AJ 2024Nature medicinePMID 38858523
Most-studied topics
The Medical Subject Headings (MeSH) PubMed indexers most often marked as a main topic, across 208 of the 208 records. They describe what the literature is about, not what Retatrutide does.
- Obesity72 papers
- Diabetes Mellitus, Type 250 papers
- Hypoglycemic Agents37 papers
- Anti-Obesity Agents36 papers
- Glucagon-Like Peptide-1 Receptor Agonists35 papers
- Incretins19 papers
- Weight Loss18 papers
- Glucagon-Like Peptide 113 papers
Key papers
Earliest indexed record
Polyzos SA (2023). Current pharmaceutical design.
PMID 38111116Most-cited paper · 932 citations
Jastreboff AM (2023). The New England journal of medicine.
PMID 37366315Most-cited #2 · 346 citations
Rosenstock J (2023). Lancet (London, England).
PMID 37385280Most-cited #3 · 334 citations
Drucker DJ (2024). Diabetes care.
PMID 38843460
Citation counts from NIH iCite, among the 208 records sampled. Titles are left out; open each record on PubMed to read it.
Identity
| Synonyms and codes | VLP-3 (RT) |
|---|---|
| Description | GIP, GLP-1 and glucagon receptor triple agonist peptide |
| Supplied form | Lyophilized powder |
As published by Vanta Labs, with its sources, on the Retatrutide page.
How these numbers were counted
- PubMed search, run November 1, 2026:
retatrutide[tiab]re-run it. Study types add PubMed’s own filters (review, clinical trial, animals not humans). - Topics: MeSH major-topic headings counted across up to 400 of the matching records; headings for study set-up (species, sex, age) are left out.
- Citations: NIH iCite citation counts for the same records.
- ClinicalTrials.gov search:
retatrutidere-run it. Any phase, any status.
This page reports what has been published and what papers say they found, with each source linked. It gives no dosing or usage information, and nothing here is a reason to use Retatrutide outside a laboratory.
Wholesale supply
Retatrutide for research, documented lot by lot.
5mg, 10mg, 20mg, 30mg vials, with a published report printing 99.512% HPLC purity. Every wholesale lot comes with its certificate of analysis, and your quote names the lot. Pricing on inquiry.
Retatrutide research questions
How much research has been published on Retatrutide?
PubMed indexes 208 records matching Retatrutide (searched November 1, 2026), including 129 reviews and 10 records indexed as clinical trials. 112 were published in the five years 2021–2025.
When was Retatrutide first described in the literature?
The earliest PubMed record matching Retatrutide is from 2023 (Polyzos SA, Current pharmaceutical design, PMID 38111116).
What topics does the Retatrutide literature cover?
The subject headings PubMed indexers most often marked as a main topic of Retatrutide papers are Obesity, Diabetes Mellitus, Type 2, Hypoglycemic Agents, Anti-Obesity Agents. These describe what the literature is about. Findings from individual papers, with their sources, are summarized on this page.
Is Retatrutide sold for human use?
No. Vanta Foundry supplies it for laboratory research use only. Not for human or veterinary use, and not a drug, food, cosmetic or dietary supplement.
Where can I buy Retatrutide wholesale for research?
From the Vanta Foundry wholesale catalog: add it to your list, choose sizes and the number of vials, and send it on WhatsApp or by email. Every wholesale lot comes with a certificate of analysis.
Research materials supplied by Vanta Foundry are for laboratory research use only. They are not for human or veterinary use and are not drugs, foods, cosmetics or dietary supplements. Websites and payment processing are business services for research-supply brands.
All compounds: research peptide publication statistics.